Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries

Value in Health

Volumn 15, Issue 1 SUPPL., 2012, Pages

  Termrungruanglert, Wichai ^a   Havanond, Piyalamporn ^a   Khemapech, Nipon ^a   Lertmaharit, Somrat ^a   Pongpanich, Sathirakorn ^a   Khorprasert, Chonlakiet ^a   Taneepanichskul, Surasak ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

cost effectiveness; developing countries; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

CANCER GRADING; CANCER INCIDENCE; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; THAILAND; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84856021752     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.007     Document Type: Conference Paper

References (62)

1. D.M. Parkin Cancer in developing countries Cancer Surv 1920 1994 519 561
2. D.M. Parkin, P. Pisani, J. Ferlay Estimates of the worldwide incidence of 25 major cancers in 1990 Int J Cancer 80 1999 827 841 (Pubitemid 29108856)
3. P. Pisani, D.M. Parkin, J. Ferlay Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden Int J Cancer 55 1993 891 903 (Pubitemid 24005331)
4. M.J. Quinn, N. Cooper, B. Rachet Survival from cancer of the uterine cervix in England and Wales up to 2001 Br J Cancer 99 Suppl. 1 2008 S59 S62
5. F.X. Bosch, M.M. Manos, N. Munoz Prevalence of human papillomavirus in cervical cancer: a worldwide perspective International Biological Study on Cervical Cancer (IBSCC) Study Group J Natl Cancer Inst 87 1995 796 802
6. N. Munoz, F.X. Bosch HPV and cervical neoplasia: review of casecontrol and cohort studies IARC Sci Publ 119 1992 251 261
7. J.M. Walboomers, M.V. Jacobs, M.M. Manos Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 1999 12 19 (Pubitemid 29406813)
8. E.M. Burd Human papillomavirus and cervical cancer Clin Microbiol Rev 16 2003 1 17 (Pubitemid 36114705)
9. G. Clifford, S. Franceschi, M. Diaz Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases Vaccine 24 Suppl. 3 2006 S3/2634
10. G.M. Clifford, J.S. Smith, T. Aguado, S. Franceschi Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis Br J Cancer 89 2003 101 105 (Pubitemid 36897943)
11. M. Giles, S. Garland Human papillomavirus infection: an old disease, a new vaccine Aust N Z J Obstet Gynaecol 46 2006 180 185 (Pubitemid 44056722)
12. S.J. Goldie, M. Kohli, D. Grima Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine J Natl Cancer Inst 96 2004 604 615 (Pubitemid 38584984)
13. N. Munoz, F.X. Bosch, S. de Sanjose Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 2003 518 527 (Pubitemid 36159887)
14. S. Deerasamee, P. Srivatanakul Cervix uteri S. Deerasamee, N. Martin, S. Sontipong, Cancer in Thailand 1992-1994 1999 IARC Lyon, France (Technical Report No. 34)
15. P. Pengsaa, S. Jindawijak Cervix uteri H. Sriplung, S. Sontipong, N. Martin, Cancer in Thailand (Vol. III) 1997 National Cancer Institute of Thailand Bangkok, Thailand
16. S.B. Chichareon Cervical cancer incidence in the south of Thailand 19881989 J Med Assoc Thai 76 1993 146 152
17. J. Sherris, I. Agurto, S. Arrossi Advocating for cervical cancer prevention Int J Gynaecol Obstet 89 Suppl. 2 2005 S46 S54
18. Bureau of Health Policy and Strategy Vital Statistics 2008 Ministry of Public Health Bangkok, Thailand
19. H. Sriplung Projection of cancer problems T. Khuhaprema, P. Srivatanakul, H. Sriplung, Cancer in Thailand 2008 National Cancer Institute of Thailand Bangkok, Thailand
20. S. Wilailak Epidemiologic report of gynecologic cancer in Thailand J Gynecol Oncol 20 2009 81 83
21. M. Lertworapreecha, P. Bhattarakosol, S. Niruthisard Detection and typing of human papillomavirus in cervical intraepitherial neoplasia (CIN) grade III by PCR and dot hybridization Southeast Asian J Trop Med Public Health 29 1998 507 511 (Pubitemid 128529669)
22. F. Breitburd, P. Coursaget Human papillomavirus vaccines Semin Cancer Biol 9 1999 431 444
23. World Health Organization WHO position on HPV vaccines Vaccine 27 2009 7236 7237
24. A.N. Burchell, H. Richardson, S.M. Mahmud Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada Am J Epidemiol 163 2006 534 543
25. S.B. Cantor, M.C. Fahs, J.S. Mandelblatt Decision science and cervical cancer Cancer 98 2003 2003 2008 (Pubitemid 37310208)
26. S.J. Goldie, M.C. Weinstein, K.M. Kuntz, K.A. Freedberg The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women Ann Intern Med 130 1999 97 107 (Pubitemid 29045357)
27. J.J. Kim, T.C. Wright, S.J. Goldie Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance JAMA 287 2002 2382 2390 (Pubitemid 34493201)
28. S.L. Kulasingam, E.R. Myers Potential health and economic impact of adding a human papillomavirus vaccine to screening programs JAMA 290 2003 781 789 (Pubitemid 37432955)
29. J.S. Mandelblatt, W.F. Lawrence, S.M. Womack Benefits and costs of using HPV testing to screen for cervical cancer JAMA 287 2002 2372 2381 (Pubitemid 34493200)
30. J.S. Mandelblatt, W.F. Lawrence, L. Gaffikin Costs and benefits of different strategies to screen for cervical cancer in less-developed countries J Natl Cancer Inst 94 2002 1469 1483 (Pubitemid 35243745)
31. E.R. Myers, D.C. McCrory, K. Nanda Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis Am J Epidemiol 151 2000 1158 1171 (Pubitemid 30451948)
32. G.D. Sanders, A.V. Taira Cost-effectiveness of a potential vaccine for human papillomavirus Emerg Infect Dis 9 2003 37 48 (Pubitemid 36110201)
33. A.V. Taira, C.P. Neukermans, G.D. Sanders Evaluating human papillomavirus vaccination programs Emerg Infect Dis 10 2004 1915 1923 (Pubitemid 39458555)
34. P. Doubilet, C.B. Begg, M.C. Weinstein Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach Med Decis Making 5 1985 157 177 (Pubitemid 16130640)
35. F.A. Sonnenber, J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338 (Pubitemid 24013155)
36. P. Prasartkul, U. Rakchanyaban Estimation generation life tables for Thailand of five-year birth cohorts: 19002000 2002 Institute for Population and Social Research, Mahidol University Bangkok, Thailand
37. P. Srivatanakul Cervix uteri T. Khuhaprema, P. Srivatanakul, H. Sriplung, Cancer in Thailand (Vol. IV) 2000 National Cancer institute of Thailand Bangkok, Thailand
38. R.P. Insinga, A.G. Glass, B.B. Rush Diagnoses and outcomes in cervical cancer screening: a population-based study Am J Obstet Gynecol 191 2004 105 113 (Pubitemid 39077962)
39. M. Pirotta, A.N. Stein, E.L. Conway Genital warts incidence and health care resource utilisation in Australia Sex Transm Infect 86 2010 181 186
40. Y. Tanapat, K. Sungkawasi, K. Tatanan Cervical cancer survival at Pramongkutklao Hospital Royal Thai Army Med J 48 1995 21 24
41. S. Srisupundit, P. Kraiphibul, S. Tangtrakul, Y. Bhamarapravati Cervical cancer survival at Ramathibodi Hospital 19791983 J Med Assoc Thai 73 Suppl. 1 1990 15 19
42. P. Pengsaa, B. Udomthavornsak, A. Hemfling Prognostic factors for survival after surgery for early stages cervical cancer Thai J Obstet Gynaecol 2 1990 29 36
43. Y. Kongthanarat Five year results of radiation therapy and radiation therapy with concomitant high dose Mitomycin-C in the treatment of the uterine cervix J Rajavithi Hosp 7 1996 25 31
44. I. Zighelboim, N.P. Taylor, M.A. Powell Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy Radiat Med 24 2006 625 630 (Pubitemid 46074905)
45. C. Lertbutsayanukul, P. Lertsangransinchai, K. Shotelersuk Results of radiation therapy in stage IB cervical carcinoma at King Chulalongkorn Memorial Hospital: fifteen-year experience J Med Assoc Thai 84 2001 S216 S227
46. S. Nishio, N. Katsumata, K. Matsumoto Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma Oncol Rep 19 2008 497 503 (Pubitemid 351176113)
47. M. Maiman, R.G. Fruchter, E. Serur Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women Obstet Gynecol 82 1993 170 174 (Pubitemid 23217653)
48. S. Cecchini, F. Carozzi, M. Confortini Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure Tumori 90 2004 225 228 (Pubitemid 38745612)
49. N. Scheinfeld, D.S. Lehman An evidence-based review of medical and surgical treatments of genital warts Dermatol Online J 12 2006 5
50. S. Mortazavi, M. Zali, M. Raoufi The prevalence of human papillomavirus in cervical cancer in Iran Asian Pacific J Cancer Prev 3 2000 69 72
51. Y. Tsao, K. Yang, C. Han Genital human papillomavirus infections in Taiwan Int J Gynaecol Obstet 44 1994 35 49
52. N. Khemapech, P. Havanond, W. Termrungruanglert Quality of life in Thai women diagnosed with genital wart, cervical cancer and cervical intraepithelial neoplasia at King Chulalongkorn Memorial Hospital ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, September 57 2010
53. L.L. Villa, R.L. Costa, C.A. Petta Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Lancet Oncol 6 2005 271 278 (Pubitemid 40590263)
54. M.R. Gold, J.E. Siegel, L.B. Russell, M.C.E. Weinstein Cost-Effectiveness in Health and Medicine 1996 oxford university press new york
55. S. Tantivess The role of HTA in the development of HPV vaccination policy in Thailand Presented at the 6th annual meeting of the HTA Singapore, June 23 2009
56. J.P. Hughes, G.P. Garnett, L. Koutsky The theoretical population-level impact of a prophylactic human papilloma virus vaccine Epidemiology 13 2002 631 639 (Pubitemid 44698466)
57. World Bank World Development Indicators 2009 World Bank Washington, DC
58. World Health Organization Macroeconomic and Health Investing in Health for Economic Development: Report for the Commission on Macroeconomics and Health, Geneva, Switzerland 2001
59. J.C. Wright, M.C. Weinstein Gains in life expectancy from medical interventions - standardizing data on outcomes N Engl J Med 339 1998 380 386 (Pubitemid 28363802)
60. The Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 2007 1915 1927
61. D.M. Harper, E.L. Franco, C.M. Wheeler Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial Lancet 367 2006 1247 1255
62. W. Huh, E. Joura, S. Garland Impact of the quadrivalent HPV 6/11/16/1/vaccine in women who have undergone definitive therapy: do these women benefit from vaccination? Presented at 41st annual meeting of Society of Gynecologic Oncologists (SGO) San Francisco, CA, March 15 2010 433 438